Miracle Therapeutics (B)

內容大綱
Supplements the (A) case, 824020. Following on the negotiations detailed in the Miracle Therapeutics (A) case, Beth Sharp and Jennifer Brilliant from Miracle Therapeutics face new challenges with their company's funding and intellectual property (IP) after several missteps. The company and its young CEO are at a crossroads and must solve the challenges faced by many early-stage life science companies. The case follows how they navigate these issues to set Miracle on the right course.
涵蓋主題
新增
新增